Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology

Riestra, Ana Cristina; Vázquez, Natalia; Chacón, Manuel; Berisa, S; Sánchez-Ávila, Ronald Mauricio; Orive, Gorka; Anitua, Eduardo; Meana, Álvaro; Merayo‐Lloves, Jesús

doi:10.1016/j.jtos.2017.01.003

Cited by 16 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ). [ 20 ] The PRGF eye drops were also manufactured, according to the protocol described by Anitua et al [ 15 ] After the surgery, the PRGF eye drops were applied topically (in the conjunctival sac) 4 times per day for 6 weeks in the affected eye.…”

Section: Methodsmentioning

confidence: 99%

Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders

et al. 2018

View full text Add to dashboard Cite

To evaluate the safety and efficacy of the surgical use of plasma rich in growth factors fibrin membrane (mPRGF) in different ocular surface pathologies.Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, superficial keratectomy, corneal perforation, and pterygium). Best corrected visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF AT (PRGF membrane absorption time), and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also performed reporting all adverse events.mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean follow-up time was 11.1 ± 4.2 (4.8–22.8) months, the mean ICT was 2.5 ± 1.1 (1.0–4.0) months, the mean mPRGF AT was 12.4 ± 2.0 (10.0–16.0) days, and for the global HTED the mean was 2.9 ± 1.2 (1–4.8) months. Results showed an improvement in BCVA in all patients, with an overall improvement of 2.9 in Vision Lines. The BCVA significantly improved (P < .05) in the groups of corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was significantly reduced (P < .05) in patients treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP remained stable (P > .05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use.The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing inflammation and fibrosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The eye drops PRGF has shown in different in vitro, in vivo, and clinical studies to have a higher concentration of growth factors, proliferation capacity, migration and tissue regeneration in the ocular surface and cornea.14 The PRGF fibrin membrane has mechanical properties and resistance that allow its use in surgical procedures, it has been shown that inside of it contains a wide range of growth factors, which are released progressively over time 15,16. It has also been shown that the PRGF membrane serves as scaffolding for cell expansion in advanced therapy studies.7…”

Section: Discussionmentioning

confidence: 99%

“…A new surgery was carried out in order to achieve the MH closure. The PRGF-membrane was prepared according to Endoret ® technology (BTI Biotechnology Institute, S.L., Miñano, Álava, Spain).7 The surgical procedure consisted in enlarging the peeling of the ILM, close to the optic nerve and the vascular arcade and tap the edges of the MH (to increase the probability of closing the MH, technique proposed by the retina surgeon: AFVS). Then, the PRGF membrane was introduced through the trocar and placed inside the MH (the thickness of the membrane was 100 µm), without pressure and without forcing the adhesion (PRGF fibrin membrane have adhesion properties when it comes into contact with the cell surface) trying to avoid the potential damage to the retinal pigment epithelium; subsequently three drops of liquid PRGF were placed in the MH, and a fluid-gas (C3F8) exchange was performed at the end of the surgery (Figure 2).…”

Section: Case Reportmentioning

confidence: 99%

“…Plasma rich in growth factors (PRGF) is a novel autologous ophthalmic therapy that contains a large number of biologically active agents, including EGF (epidermal growth factor), PDGF (platelet-derived growth factor), insulin-like growth factor 1, fibronectin and vitamin A,5 that promote tissue regeneration, healing modulation and anti-inflammatory properties, among others.5 PRGF-Endoret technology can be used to obtain different formulations, like eye drops and membranes, for the treatment of several ophthalmic diseases.6 The PRGF membrane has similar mechanical and biological properties to the amniotic membrane7 and it has been used in ocular and corneal surface surgery with good clinical results.8…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors</p>

Sánchez-Ávila¹,

González²,

Sanz³

et al. 2019

IMCRJ

Self Cite

View full text Add to dashboard Cite

Purpose To describe the case of a patient with a recurrent large myopic macular hole (MH), who was successfully treated with a plasma rich in growth factors (PRGF) membrane. Case Report A 71-year-old patient presented a myopic MH in his right eye. One month later, pars plana vitrectomy with internal limiting membrane (ILM) peeling was performed, achieving closure of the MH. Three months later a recurrence was observed (700 µm) without visual acuity (VA) improvement. A new surgery was carried out placing an autologous PRGF-membrane into the MH, and performing a fluid-gas exchange at the end of the surgery. After two months of follow-up, the MH was completely closed, obtaining the anatomic recovery of the foveal depression, and improving the VA to 0.1. No adverse reactions were associated with the use of PRGF and there were no new recurrences of the MH in a follow-up period of six months. Conclusion The use of PRGF-membrane can be used as adjunctive therapy in the surgical repair of recurrent large myopic MHs, thus improving anatomic and visual outcomes.

show abstract

“…Regarding the industrialization of PRGF eye drops, there are studies of preservation and biological activity for 3 months in human use, with good outcomes in the care for patients with severe dry eye that do not respond to conventional therapy [ 39 ], with special success in neutrophic cases [ 40 ]. Finally, PRGF could be used to support the growth of limbal stem cells [ 41 , 42 ].…”

Section: Hemoderivativesmentioning

confidence: 99%

Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Villatoro

Fernández

Claros

et al. 2017

IJMS

View full text Add to dashboard Cite

Dry eye syndrome is a complex and insidious pathology with a high level of prevalence among the human population and with a consequently high impact on quality of life and economic cost. Currently, its treatment is symptomatic, mainly based on the control of lubrication and inflammation, with significant limitations. Therefore, the latest research is focused on the development of new biological strategies, with the aim of regenerating affected tissues, or at least restricting the progression of the disease, reducing scar tissue, and maintaining corneal transparency. Therapies range from growth factors and cytokines to the use of different cell sources, in particular mesenchymal stem cells, due to their multipotentiality, trophic, and immunomodulatory properties. We will review the state of the art and the latest advances and results of these promising treatments in this pathology.

show abstract

Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology

Cited by 16 publications

References 35 publications

Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders

Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders

<p>Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors</p>

Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Contact Info

Product

Resources

About